BriaCell Therapeutics Corp. (BCTX) Net Income towards Common Stockholders (2021 - 2026)

BriaCell Therapeutics has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$7.4 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders fell 17.24% year-over-year to -$7.4 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$31.7 million (down 3.6% YoY) and the FY2025 annual result came in at -$26.3 million, down 449.14% from the prior year.
• Net Income towards Common Stockholders was little changed at -$7.4 million in Q2 2026 per BCTX's latest filing, from -$7.4 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $6.0 million in Q4 2023 and troughed at -$11.9 million in Q3 2023.
• A 5-year average of -$5.7 million and a median of -$6.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 3672.85% in 2022, then surged 642.37% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$1.1 million in 2022, then soared by 642.37% to $6.0 million in 2023, then sank by 196.68% to -$5.8 million in 2024, then tumbled by 43.35% to -$8.3 million in 2025, then increased by 10.66% to -$7.4 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$7.4 million, -$7.4 million, and -$8.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.